Imugene Limited (AU:IMU) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Imugene Limited reports notable success in its Phase 1b clinical trial of azer-cel, an allogeneic CD19 CAR T therapy, with three patients achieving complete responses in the treatment of relapsed/refractory diffuse large B cell lymphoma. The trial, which involves patients who had previously undergone multiple treatments, including autologous CAR T therapies, has demonstrated the safety and tolerability of azer-cel. Imugene plans to continue enrolling patients and monitor the durability of the responses, with the Cohort B regimen potentially advancing to FDA Phase 2/3 trials.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.